Ambion acquired for $273 million

Austin-based Ambion Inc. has sold its research division, the bulk of the company,to Norwalk, Conn.- based Applera Corp. for $273 million in cash. Applera's Applied Biosystems Group will run Ambion, which had $52 million in 2005 revenue. CEO Matt Winkler (the new multimillionare of Austin TX), plans now to take Ambion's remaining 100 employees to spin off the company's $5 million diagnostic unit. That company, which will be called Asuragen, will develop cancer based molecular diagnostic tests.

Ambion acquired for $273 million

BioBOOM Op/Ed: Well the rumors seem to be true. Nice move by the wizard of RNA. Winkler gets a huge cash infusion into his future efforts in MDX and ABI gains one great brand name for RNA research tools. Only 2 questions remain: will ABI protect the brand or ruin it, time will tell and will micro-rna be big for diagnostics (We think YES). Know this, there were many players looking at this opportunity including Invitrogen, Qiagen, Eppendorf, Sigma and others. But looks like ABI pulled the trigger and came in closest to the $300mil asking price.

No comments:

Blog Archive